Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Jones, L; Atkinson, A; Bates, G; McCoy, E; Porcellato, LA; Beynon, C; McVeigh, J; Bellis, MA
Languages: English
Types: Article
Subjects: RA0421, RA
Background: Many developed countries are facing a major challenge to improve identification of individuals acutely and chronically infected with hepatitis C virus (HCV) infection. We explored the views and experiences of people who inject drugs (PWID) in relation to HCV testing, and diagnosis through a review and synthesis of qualitative research.\ud \ud Methods: Based on the thematic synthesis of qualitative research. Searches were conducted in 14 databases and supplemented by reference checking, hand searching of selected journals, and searches of relevant websites. Studies of any qualitative design that examined the views and experiences of, and attitudes towards, HCV testing and diagnosis among PWID or practitioners involved in their care were included. Key themes and sub-themes were systematically coded according to the meaning and content of the findings of each study which proceeded to the preparation of a narrative account of the synthesis.\ud \ud Results: 28 qualitative studies were identified. We identified a number of overarching descriptive themes in the literature, finding overall that PWID hold complex and differing views and experiences of testing and diagnosis. Three major themes emerged: missed opportunities for the provision of information and knowledge; shifting priorities between HCV testing and other needs; and testing as unexpected and routine. Evidence of missed opportunities for the provision of knowledge and information about HCV were clear, contributing to delays in seeking testing and providing a context to poor experiences of diagnosis. Influenced by the nature of their personal circumstances, perceptions of the risk associated with HCV and the prioritisation of other needs acted both to encourage and discourage the uptake of HCV testing. Undergoing HCV testing as part of routine health assessment, and an unawareness of being testing was common. An unexpected positive diagnosis exacerbated anxiety and confusion.\ud \ud Conclusions: This review has identified that there are modifiable factors that affect the uptake of HCV testing and experiences of HCV diagnosis among PWID. Intervention development should focus on addressing these factors. There is a need for further research that engages PWID from a diverse range of populations to identify interventions, strategies and approaches that they consider valuable.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Astone, J. M., Strauss, S. M., Munoz-Plaza, C., Hagan, H., & Des Jarlais, D. C. (2005). Providing support to drug users infected with hepatitis C: the role of methadone maintenance treatment staff.
    • Journal of Maintenance in the Addictions, 3(1), 33-46.
    • Bruce, R. D. (2012). One stop shopping - Bringing services to drug users. Journal of International Drug Policy, 23, 103-110.
    • Bruggman, P. (2012). Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. Journal of Viral Hepatitis, 19, 829-835.
    • Carrier, N., LaPlante, J., & Bruneau, J. (2005). Exploring the contingent reality of biomedicine: injecting drug users, hepatitis C virus and risk. Health, Risk & Society, 7(2), 123-140.
    • Copeland, L. (2004). The drug user's identity and how it relates to being Hepatitis C antibody positive: a qualitative study. Drugs-Education Prevention and Policy, 11(2), 129-147.
    • Corey, K. E., Mendez-Navarro, J., Gorospe, E. C., Zheng, H., Chung, R. T. (2010). Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. Journal of Viral Hepatitis, 17, 201-207.
    • Craine, N., Walker, M., Carnwath, T., & Klee, H. (2004). Hepatitis C testing and injecting risk behaviour: the results of a UK based pilot study. International Journal of Drug Policy, 15(2), 115-122.
    • Cullen, W., Kelly, Y., Stanley, J., Langton, D., & Bury, G. (2005). Experience of hepatitis C among current or former heroin users attending general practice. Irish Medical Journal, 98(3), 73-74.
    • Cullen, W., Stanley, J., & Langton, D. (2006). Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. British Journal of General Practice, 56(532), 848-56.
    • Cullen, B. L., Hutchinson, S. J., Cameron, S. O., Anderson, E., Ahmed, S., Spence, E., et al. (2012).
    • Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practicebased case-finding intervention. Journal of Public Health, 34(1), 14-23.
    • Morris, K. (2011). Tackling hepatitis C: a tale of two countries. The Lancet, 377, 1227-1228.
    • Mühlberger, N., Schwarzer, R., Lettmeier, B., Sroczynski, G., Zeuzem, S., & Siebert, U. (2009).
    • HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health, 9, 34.
    • Munoz-Plaza, C. E., Strauss, S. M., Astone, J. M., Des Jarlais, D. C., & Hagan, H. (2005). HCV (Hepatitis C virus) pre-test and post-test counseling services at drug treatment programs: Missed opportunities for primary prevention. Contemporary Drug Problems: An Interdisciplinary Quarterly, 32(4), 655-675.
    • Munoz-Plaza, C. E., Strauss, S. M., Astone, J. M., Jarlms, D. C. D., & Hagan, H. (2004). Drug treatment programs as sites of opportunity for the delivery of hepatitis C prevention education: Client and staff perspectives. Journal of Drug Issues, 34(4), 861-878.
    • Munoz-Plaza, C., Strauss, S. M., Tiburcio, N., Astone-Twerell, J. M., Des Jarlais, D. C., Gwadz, M., et al. (2010). Perspectives on the hierarchy of HIV and hepatitis C disease: consequences for drug treatment program patients. Journal of Drug Issues, 40(2), 517-535.
    • Study Khaw et al., 2007
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article